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Abstract
Sepsis is a pervasive condition that carries a tremendous burden of disease in the form of
financial cost, morbidity, and mortality. Culturing methods slow clinicians’ ability to
begin focused treatment, and increased antimicrobial resistance only intensifies the need
for improved diagnostic tools. Rapid molecular diagnostic tests can shorten time to
identify organisms, reduce inappropriate antibiotic treatment, and improve patient
outcomes. A newly approved test has proven fast and accurate for identification and
susceptibility, but has not been studied in regard to clinical outcomes. Our study will
compare the effect of the Accelerate™ system versus standard identification and
susceptibility tests on patient length of stay. In a randomized controlled trial, we will
use the Accelerate Pheno™ system to identify microbes and drug-resistance in septic
critical care patients. We expect that diagnosis using this test will result in faster, more
focused therapy, which will shorten hospital stays and save lives.
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Chapter 1: Introduction
1.1 Background
Sepsis is a critical illness that has plagued humankind for millennia, with literary
references to its destructive course reaching as far back as Homer’s Iliad, Hippocrates’
Corpus Hippocratum, and the writings of Galen.1 Defined as, “life-threatening organ
dysfunction caused by a dysregulated host response to infection,2” sepsis continues to
cause tremendous suffering, despite our best efforts to understand and treat it. Sepsis
does not discriminate on the basis of geographical location, socio-economic status, or
racial differences and can strike both the octogenarian and the newborn. The worldwide
mortality rate for patients with sepsis is a staggering 35.3%.3 The most severe
manifestation of sepsis—septic shock—causes cellular, circulatory, and metabolic
dysfunction that can increase mortality upward of 40%.2,4 In the United States, infectious
disease is one of the ten leading causes of mortality, and more people die in the intensive
care unit (ICU) from sepsis than from heart attack, stroke, congestive heart failure, or
acute respiratory failure.5-8
Despite the history and prevalence of sepsis, there is no single diagnostic test with
which to diagnose it. Instead, providers must draw conclusions from a combination of
clinical, radiological, laboratory, and microbiological findings.2 Identification of the
pathogen is a crucial yet time-consuming step in this process that is necessary to inform
our choice of antimicrobial treatment. For patients who develop sepsis, time to effective
therapy is of the essence, particularly in cases of septic shock, where it has been shown
that mortality increases 7.6% for every hour that appropriate antibiotic treatment is
1

delayed.9 For patients infected with multidrug-resistant organisms (MDROs), failure to
find a timely treatment can be fatal.10-12 And while the pharmaceutical world races to stay
ahead of these “super bugs” by developing ever-stronger antimicrobials, the bugs are
gaining ground.
Less than a year after penicillin was introduced into practice, four penicillinresistant Staphylococcus strains were found in patients receiving the new antibiotic.13
Antimicrobial resistance is now a presence in every country, and the World Health
Organization has declared it a serious threat to global public health.14 Misuse of
antibiotics in agriculture and human medicine has only accelerated the rate of bacterial
resistance.14,15 For example, between 2010 and 2012, the incidence rate of carbapenemresistant Klebsiella species in United States hospitals jumped from 1.6% to 10.4%.16 And
while the spread of MDROs was historically limited to hospital settings, it is now seen as
an emerging community-acquired threat as well.17 Over 2 million illnesses and
approximately 23,000 deaths are attributed to antibiotic resistance each year in this
country.18 MDROs inflict an enormous financial burden as well. In the US, resistant
organisms cost the healthcare system an additional $21-34 billion annually.17
In order to identify (ID) pathogens that cause blood stream infections (BSIs), a
sample of blood must be incubated, monitored for microbial growth, and then plated.
Antimicrobial susceptibility tests (ASTs) are then performed to determine appropriate
treatment.19 It can take 24-72 hours for a blood culture sample to turn positive for growth,
and another 24-48 hours to determine antimicrobial susceptibility using traditional
methods.19 Rapid diagnostic tests using various molecular techniques involving DNA
amplification/hybridization, nucleic acid probes, magnetic resonance, and mass
2

spectrometry have been developed to shorten time to identification of pathogens as well
as resistance.15,20 Studies have shown that these products have the potential to improve
outcomes regarding mortality, length of stay, and lower healthcare costs.21
1.2 Statement of Problem
Despite many diagnostic products now available for rapid identification of blood
borne microbes and drug susceptibility, no single method has shown sufficient sensitivity
or specificity to identify all sepsis-related microorganisms.21 Furthermore, there have
been few prospective, randomized clinical trials that directly compare rapid diagnostics to
blood cultures, particularly with respect to clinical outcomes.21
In February 2017, the FDA approved a new diagnostic test, the Accelerate
Pheno™ system (AxDx), designed to rapidly identify the most common pathogens
associated with sepsis. Using a blood culture sample, AxDx can provide ID and AST
results in approximately 7 hours, one to two days faster than conventional culture and
susceptibility methods (Fig. 1).22,23 AxDx can recommend a minimum inhibitory
concentration (MIC) based on morphokinetic response in the AST phase. The system
also has the ability to confirm that a culture is monomicrobial and to test for multiple
organisms in a polymicrobial sample.24
To date, there have been no prospective, randomized clinical trials comparing
AxDx to standard lab methods in relation to clinical outcomes. With this study we intend
to show an improvement in patient outcomes using diagnostic information gained from
AxDx to guide more immediate and appropriate treatment for sepsis.
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1.3 Goals and Objectives
The goal of this randomized controlled trial is to determine whether the use of
AxDx to guide treatment will reduce length of stay in the intensive care unit (ICU LOS)
for patients with sepsis, when compared to the use of standard laboratory methods.
Along with our primary outcome, we will investigate effects on mortality, hospital length
of stay (HLOS), and time to appropriate treatment (TAAT). To achieve the
aforementioned goals of this study, we propose the following objectives:
I.
II.

Incorporate the AxDx into laboratory flow.
Emphasize current definitions and diagnostic criteria for sepsis and septic
shock in the ICU.

III.

Establish coordinated communication of results between microbiology
department, antimicrobial stewardship team, and medical providers.

IV.

Gain information on our patient population in terms of demographics,
healthcare setting, source of infection, comorbidities, bacterial community
composition, and antibiotic resistance.

1.4 Hypothesis
ICU LOS (measured as mean number of days) will be significantly different in
septic ICU patients whose treatment is guided by AxDx run concurrently with standard
culturing compared to those treated based on standard culturing alone.

5

1.5 Definitions
Antimicrobial resistance: the ability of microbes to resist the effects of drugs, allowing
them to multiply and pass these traits on to others.
Antimicrobial stewardship program (ASP): clinicians, pharmacists, and staff with
expertise in infectious disease, who oversee selection and dosing of antimicrobial therapy
in order to minimize adverse reactions and reduce potential for antimicrobial resistance.25
Antimicrobial susceptibility test (AST): microbes are exposed to various drugs to
determine which will be most effective in treating an infection.
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF): Molecular
process wherein a microbial colony is mixed with a matrix and irradiated by laser, thus
becoming electrically charged and vaporized. An analyzer separates the molecules and
compares their flight pattern to a database for species identification.26
Minimum inhibitory complex (MIC): the lowest concentration of an antimicrobial
agent that will inhibit visible growth of an organism.
Peptide nucleic acid fluorescence in situ hybridization (PNA FISH): Molecular
process using genetic probes labeled with fluorescent dye. The probe binds to a
particular nucleic acid sequence on a microbial chromosome allowing visual
identification of microbial species.27
Polymerase Chain Reaction (PCR): molecular technique using primers to locate
specific nucleic acid sequences, which are then multiplied exponentially for species
identification. PCR can be multiplexed, allowing more than one species in a sample to be
identified.28
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Chapter 2: Review of the Literature
2.1 Introduction
This study will investigate whether the use of a new molecular rapid diagnostic
test (mRDT), Accelerate Pheno™ (AxDx), to identify infectious pathogens will
ultimately impact patient outcomes in the ICU. A comprehensive literature review was
undertaken to identify studies comparing clinical outcomes of rapid tests to current
standard microbiology methods. We searched PubMed, Embase, SCOPUS, Google
Scholar, and Web of Science from August 2017-August 2018 for the following keywords
and phrases: sepsis, severe sepsis, septic shock, septicemia, bacteremia, fungemia, rapid
molecular diagnostic test, matrix-assisted laser desorption/ionization time-of-flight or
MALDI-TOF, polymerase chain reaction or PCR, peptide nucleic acid fluorescence in
situ hybridization or PNA FISH, antimicrobial resistance, antimicrobial stewardship,
length of stay, mortality, and clinical outcomes. Randomized controlled trials,
prospective and retrospective cohort trials, observational studies, consensus statements,
conference publications, meta-analyses, and systematic reviews were included in the
search. Articles from peer-reviewed sources were reviewed by title and abstract for
relevancy. Articles referenced within these studies were also considered. The following
represents a review of key studies examining the relationship under investigation.
2.2 Review of Sepsis and Septic Shock Diagnosis
In order to show the potential benefits of AxDx, we first had to assess the best
method for identifying a septic population in the ICU. Despite our long-standing
familiarity with this condition, the scientific community continues to debate over the
defining characteristics of sepsis and the best clinical criteria for diagnosis. In the past 30
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years, leaders in the infectious disease community have developed multiple iterations of
the defining features of sepsis and how to approach it clinically.1-3
In 2016, the Third International Consensus Definitions for Sepsis and Septic
Shock (Sepsis-3) task force scrutinized the 2001 definition3 of sepsis, as well as previous
diagnostic clinical criteria.4 They concluded that sepsis be defined as, “life-threatening
organ dysfunction caused by a dysregulated host response to infection.”4 The Sepsis-3
task force emphasized that, although sepsis-induced organ dysfunction may not manifest
clinically, sepsis should be suspected in any patient with infection. Conversely, newly
observed organ dysfunction may be the only clinical sign of underlying infection.
In 1992, the criteria for systemic inflammatory response syndrome (SIRS)—the
clinical manifestation of immune response to inflammation—were recommended as the
most effective method of identifying sepsis.5 Meeting two or more of the SIRS criteria
(Table 1) was an indication of developing severe sepsis. Sepsis-3, however, no longer
recommends its application in this context.4 Sepsis triggers both inflammatory and noninflammatory responses, along with non-immunologic processes affecting cardiovascular,
autonomic, metabolic, and neuronal pathways, and the task force concluded that SIRS did
not sufficiently address our greater understanding of the condition.
Table 1. Systemic Inflammatory Response Syndrome (SIRS)
Two or more of the following:
Temperature

Heart rate

Respiratory rate

White blood cells

>38ºC or <36ºC

>90/min

>20/min or

>12000/mm3 or <4000/mm3

PaCO2 <32 mm Hg

or >10% immature bands

Adapted from Bone et al.2
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Kaukonen et al (2015), in an observational study conducted over 14 years at 172
ICUs in Australia and New Zealand, found that 1 in 8 patients with severe sepsis were
missed using SIRS criteria.6 These patients, 12.1% of the study population, suffered
significant morbidity and mortality despite meeting fewer than 2 SIRS criteria. In a
follow-up study, sparked by dissent from SIRS supporters7, Kaukonen et al (2018)
conducted another large study of >130,000 septic patients that revealed alarming
disparity between various combinations of SIRS criteria as they relate to mortality.8 For
example, patients who met 2 SIRS criteria, high respiratory rate and high temperature,
had a mortality rate of 11.5%, while patients with the same SIRS score due to low WBC
and high heart rate had a 30.8% mortality. Similarly, patients with only low WBC (SIRS
score of 1) had a 20.0% mortality rate, which was higher than 88% of the patients with
SIRS scores of 2. These findings point to the fallibility of using any two SIRS criteria as
a definitive marker for sepsis and bring into question its use in clinical practice as well as
research studies.
As an alternative to SIRS, the Sepsis-3 task force determined that sepsis
diagnoses be based on clinical impression and Sequential [Sepsis-related] Organ Failure
Assessment (SOFA) score ≥2 (Table 2).4 In their evaluation of sepsis criteria validity,
Seymour et al (2016) found that, in ICUs, the predictive validity of SOFA for hospital
mortality was statistically greater (AUROC=0.74 [95% CI, 0.73-0.76]) than SIRS
(AUROC=0.64 [95% CI, 0.62-0.66]; P < .001).9 Cases were categorized into deciles of
baseline risk. Patients in the ICU with ≥2 SOFA score saw a 3- to 11-fold increase in
mortality depending on risk decile compared to those with ≥2 SOFA score, while those
with ≥2 SIRS criteria saw only a 1- to 2-fold increased rate of mortality compared to
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those with ≥2 SIRS criteria. Likewise, in a retrospective cohort analysis of 184,875
patients admitted to ICUs in Australia and New Zealand, Raith et al (2017) reported that
SOFA criteria demonstrated a more accurate prognosis of outcomes than SIRS. 10
Patients with ≥2 SOFA score had a significantly incremental increase in risk of longer
ICU stay (>3 days) and mortality at all deciles of baseline risk than those meeting ≥2
SIRS criteria.
Table 2. Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score
1 point

2 points

<400

<300

Respiration
PaO2/FiO2, mm Hg

3 points

4 points

<200

<100

with respiratory support
Coagulation
Platelets, ×103/μL
Liver
Bilirubin, mg/dL
(μmol/L)
Cardiovascular

<150

<100

<50

1.2-1.9

2.0-5.9

6.0-11.9

(20-32)

(33-101)

(102-204)

MAP <70 mm

CNS
Glasgow Coma Scale
Renal
Creatinine, mg/dL
(μmol/L) or urine output

Hg

DA <5 or
dobutamine
(any dose)

13-14

10-12

1.2-1.9

2.0-3.4

(110-170)

(171-299)

<20

>12.0 (204)

DA 5.1-15 or EPI

DA >15 or EPI >0.1

≤0.1or NE ≤0.1*

or NE >0.1*

6-9

<6

3.5-4.9

>5.0

(300-440)

(440)

or <500mL/day

or <200mL/day

Abbreviations: CNS, central nervous system, DA, dopamine, EPI, epinephrine, GCS, FiO2, fraction of inspired oxygen,
MAP, mean arterial pressure, NE, norepinephrine, PaO2, partial pressure of oxygen
*Adrenergic agents dosed in μg/kg/min for at least 1 hour

Adapted from Vincent et al.11

Our review of the literature supports SOFA as a highly effective tool for
evaluating septic patients in the ICU. The choice to use it as inclusion criteria will allow
us to identify those most at risk for lengthy hospital stays and higher mortality.
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2.3 Review of Septic Patient Populations
Blood stream infection (BSI) presents with a wide spectrum of severity, from
transient, self-resolving illness to profound inflammatory response that leads to high rates
of morbidity and mortality.4 In order to effectively power our study of AxDx, the
following review was focused on identifying the population most at risk for poor
outcomes due to BSI. A retrospective cohort study by Rhee et al (2017), reviewing
nearly 3 million adult electronic health records (EHRs) at 409 US hospitals, used the
updated Sepsis-3 criteria of ≥2 SOFA score to identify patients with sepsis. Within this
population they found a mean ICU LOS of 6.4 days (SD = 8.8), a mean HLOS of 12.0
days (SD = 12.1), and an estimated national in-hospital mortality rate of 15.6% (95% CI,
14.8-16.5).12 A retrospective EHR review by Novosad et al (2016) was performed for the
Centers for Disease Control “Morbidity and Mortality Weekly Report” using the
discharge codes for sepsis recommended by Sepsis-3.4,13 Of the 246 adult EHR from 4
different New York hospitals, 26% of adults with sepsis died, 6% were discharged to
hospice, and the median HLOS was 9 days (ICU LOS was not assessed). Another
retrospective study of 2.5 million cases stratified historic diagnoses of sepsis, severe
sepsis, and septic shock according to the new Sepsis-3 guidelines.4,14 Those with
discharge codes corresponding with the task force criteria of ≥2 SOFA score were
classified as septic. The study revealed mean HLOS of 10 days (SD = 12.4) and mean
ICU LOS of 6.2 days (SD = 8.1). Mortality rates for sepsis were 14.9%.14
A study by Lilly et al (2017) looking at trends from 160 ICUs in the US found
that the most common admission diagnosis was sepsis (8.5%), followed by respiratory
failure (6.9%), acute coronary syndrome (6.9%), cardiac arrest (6.5%), cerebral vascular

13

accident (6.3%), GI bleed (5.4%), pneumonia (4.2%), trauma (4.1%), and congestive
heart failure (4.0%).15 Data from the most recent cohort (2013, N = 155,177) showed
mean ICU LOS of 3.00 days (SD = 3.85) and 5.7% mortality. In the same year looking
at the hospital population (N = 147,337), average HLOS was 7.42 days (SD = 7.21) days
and mortality rate was 8.7%.
These findings show that not only does sepsis make up a significant portion of
critical illness, but that sepsis patients spend much more time in the ICU than those with
other serious conditions. On top of this they suffer from high rates of mortality, roughly 3
times greater than the average critical care patient. By selecting septic ICU patients who
meet SOFA criteria, our study will target those who stand to benefit most from quick
identification and treatment of infectious pathogens.
2.4 Review of Molecular Rapid Diagnostic Tests
In light of the significant morbidity and mortality caused by sepsis, the Infectious
Diseases Society of America supports the use of rapid molecular diagnostic tests
(mRDTs) and recognizes their potential to improve patient outcomes.16 A variety of
mRDTs have been developed to identify bacteria, viruses, and fungi faster than the
current gold standard of conventional culture techniques. The three major categories of
molecular techniques are PCR or other microarrays, PNA-FISH, and MALDI-TOF
(definitions in Ch. 1). In a 2017 systematic review of 31 studies, Timbrook et al found
that, in general, mRDT led to improvements in LOS, mortality, and time to appropriate
antimicrobial treatment (TAAT).17 However, the reviewers also found that some studies
were not powered sufficiently to detect outcomes, while others were not designed to limit
bias and reduce confounding. This limited their success in observing significant
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differences between control and intervention and cast some doubt on their findings. Our
review targeted studies examining patient outcomes, particularly in the ICU, when
mRDTs were compared to standard lab methods. The most robust research to date on the
aforementioned mRDT techniques is presented below.
The Verigene Blood Culture system (Luminex Corp.) is a multiplexed PCR assay
that can detect twelve gram-positive bacterial species plus six resistance markers and nine
gram-negative species plus three resistance markers directly from positive blood culture
bottles.18 Walker et al (2016) designed a quasi-experimental study comparing outcomes
after ID and AST using Verigene for Gram-negative bacteria to standard ID and AST
procedures.19 An antimicrobial stewardship program (ASP) was present throughout the
study. The assay was run on blood culture samples immediately after they signaled
positive. Results showed significantly reduced ICU LOS, from 16.2 to 12.0 days (P
= .03). The rate of 30-day overall hospital mortality decreased by over half (19.2% to
8.1%; P = 0.04). When analyzed with multivariate logistic regression, however, data
showed a significant association between decreased 30-day mortality for ICU patients
and the intervention (odds ratio, 0.81 [95% CI, 0.67-0.98]; P = .03). In cases of BSI
caused by extended-spectrum beta-lactamase bacteria (ESBL), TAAT was reduced
significantly from 41.4hr (SD = 9.0) to 7.3hr (SD = 9.0) (P = 0.04). In this quasiexperimental study, multi-drug resistant (MDR) bacteremia, including ESBL and
carbapenem-resistant Enterobacteriaceae (CRE) sources, was associated with 12 of the 19
deaths in the control group compared to 1 of the 8 deaths in the Verigene group (P = .03).
The study found no significant difference in HLOS or TAAT for other infections.

15

One limitation of this and many of the studies examined in our literature review is
the quasi-experimental study design, typically performed in a pre- and post-intervention
timeline. A principal problem inherent in these studies is lack of 1:1 randomization and,
therefore, inability to control for confounding variables such as changes in hospital staff,
microbial communities, and local resistance.20 Due to the retrospective nature of Walker
et al, one cannot assume that outcomes observed during the intervention period were a
direct result of the use of Verigene.19 Another limitation of this study was the evaluation
of Verigene for gram-negative species only. While gram-negative species are associated
with greater resistance and higher sepsis mortality rates (53.7% [SE = 0.3]), grampositive bacteria still account for a considerable percentage of deaths in the US (42.3%
[SE = 0.3]).21 These limitations justify the need for a randomized controlled trial in which
patients with BSI can be tested for the all of the common infectious causes of sepsis.
There are also considerable weaknesses in the design and application of Verigene.
The system requires two different cassettes to process Gram-positive and Gram-negative
samples.18 Samples cannot be analyzed directly from blood culture bottles, but must first
be Gram stained—a process performed by lab technicians that adds extra hands-on time.
Another drawback of Verigene is its unreliability in detecting polymicrobial samples as
well as identifying resistance genes.22-24 In an assessment of Verigene by Bhatti et al
(2014), the test failed to detect resistance based on the genotypic markers included in its
screening panel.24 The researchers discovered samples containing strains of P.
aeruginosa that turned out to be phenotypically resistant. As stated by Maurer et al
(2017), there is not always a direct correlation between the presence of a genetic
resistance marker and phenotypic resistance.25 This is why disk diffusion—where
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resistance and susceptibility are exposed, regardless of genotype—remains the gold
standard AST. The obvious drawback of this method is the 24-48 hour waiting period.
An ideal mRDT would able to identify gram-positive, gram-negative, mixed infections,
and also provide an accurate AST result in less time than the gold standard.
MALDI-TOF is another rapid diagnostic modality that has the ability to detect
multiple organisms in a sample. Perez et al (2013) compared this method to conventional
techniques in a quasi-experimental study at an academic hospital.26 Adult patients were
enrolled with gram-negative BSI confirmed by Gram stain, and clinical outcomes
evaluated included LOS, mortality, and TAAT. An ASP was in place throughout the
study. AST in the both groups was performed via BD Phoenix (Becton, Dickinson and
Company). ICU LOS was 7.3 days (SD=8.5) for the control group compared to 6.3 days
(SD=8.7) for the intervention (P = .05). ICU LOS from the onset of BSI, however, was
not found to be significantly different (P = .09). Total HLOS and HLOS from onset of
BSI were reduced significantly in the MALDI-TOF group, from roughly 12 to 9 days and
10 to 8 days respectively (P = .01 for both). TAAT in the control group was considerably
slower at a mean 75hr (SD=48) compared to the mean 29hr (SD=17) in the intervention
group (P = .004). After multivariate analysis, decreased HLOS was independently
associated with the intervention (hazard ratio, 1.38 [95% CI, 1.01–1.88]) as well as
appropriate antibiotic therapy at 48 hours (hazard ratio, 2.9 [95% CI, 1.15–7.33]).
While this study showed positive outcomes using MALDI-TOF, there are
considerable weaknesses when comparing its methods and rapid test choice to our
proposed research. While the MALDI-TOF method does allow for detection of multiple
microbes in a sample, colonies must first be isolated. This involves bench time as well as
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an incubation period. A limitation of Perez et al’s design was enrollment at a single
hospital and inclusion of only patients with monomicrobial, gram-negative BSI. They
excluded any patients with gram-positive bacterial, fungal, or polymicrobial BSI. There
was no difference in AST methods between the two arms of the study, which limits the
potential effect of the rapid test. As mentioned earlier, mRDTs that include AST can cut
an entire day off susceptibility wait times. The use of AxDx that provides both ID and
AST in our study has the potential to show a greater difference in outcomes. Moreover,
the inclusion of multiple hospital ICUs and septic patients with any type of BSI will
power our study to demonstrate more significant differences in outcomes than those
found by Perez and colleagues.
A thorough search for studies examining the use of PNA-FISH for BSI yielded
mixed results. The majority of studies examining clinical outcomes were quasiexperimental or case-control designs examining PNA-FISH for a limited group of
bacteria, i.e. only Candida spp. or coagulase-negative staphylococci.27-32 The most robust
study by Forrest et al (2008) compared a PNA-FISH test (AdvanDx, Inc.) for
Enterococcus species, including E. faecalis and E. faecium, to conventional cultures.28
The quasi-experimental, multi-center study enrolled all patients with blood cultures
containing gram-positive cocci in pairs. An ASP was on-hand throughout the study. In
patients with E. faecium bacteremia there was a reduction in 30-day mortality from 29%
to 12% (P = .039) and a significant decrease in TAAT (P < .001) between control and
intervention period. This study was limited by focusing on a very specific group of
pathogens as well as its quasi-experimental design.
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In February of 2017, the FDA approved AxDx, a new mRDT using FISH probes
for genotypic ID and morphokinetic analysis for phenotypic susceptibility. AxDx is run
directly on blood from positive blood culture bottles. Unlike previous PNA-FISH tests,
AxDx has the ability to simultaneously target the most common sepsis-causing grampositive and gram-negative bacteria, as well as two Candida species (Table 3).

Table 3. Accelerate Pheno™ ID Panel

Gram+ Bacteria

Gram- Bacteria

Fungi

Staphylococcus
• S. aureus
• S. lugdunensis
• S. capitis
• S. epidermidis
• S. haemolyticus
• S. hominis
• S. lugdunensis
• S. warneri

Klebsiella
• K. oxytoca
• K. pneumoniae

Candida

Enterococcus
• E. faecalis
• E. faecium
• Enterococcus spp. other
than E. faecalis
Streptococcus
• S. agalactiae
• S. gallolyticus
• S. mitis
• S. oralis

• C. albicans
• C. glabrata

Enterobacter
• E. cloacae
• E. aerogenes

Proteus
• P. mirabilis
• P. vulgaris
Citrobacter
• C. freundii
• C. koseri

Other
• E. coli
• S. marcescens
• P. aeruginosa
• A. baumannii

• S. pneumoniae
Adapted from Accelerate Diagnostics, Inc.33

AxDx differs from the techniques mentioned above in that it utilizes digital
microscopy to analyze individual cells and has the ability to identify one to four different
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species in a single sample.18 For AST it analyzes cell division, colony growth patterns,
and morphological changes in response to antimicrobials using dark field microscopy and
compares results to a compiled database.18 From this information, AxDx delivers
phenotypic AST as well as some phenotypic resistance results (Table 4). 18 As mentioned
previously, phenotypic expression of resistance is a more reliable indicator of successful
therapy than genetic markers, which are not always detected via molecular methods.25

Table 4. Accelerate Pheno™ Antibiotic Susceptibility/Resistance Panel

Phenotypic
Susceptibility*

Phenotypic Resistance

• Ampicilin

• Ampicillin-Sulbactam

• Ceftaroline

• Piperacillin-Tazobactam

• Cefepime

• Ertapenem

• Ceftazidime

• Meropenem

• Ceftriaxone

• Amikacin

• Erythromycin

• Gentamicin

• Daptomycin

• Tobramycin

Clindamycin

• Linezolid

• Ciprofloxacin

S. lugdunensis

• Vancomycin

• Aztreonam

CNS spp.

• Cefoxitin

S. Aureus
S. lugdunensis
CNS spp.
• Erythromycin/

Adapted from Accelerate Diagnostics, Inc.33

AxDx is capable of processing samples from positive blood culture to ID and
AST in approximately 7 hours. In a performance study by Marschal et al (2017), AxDx
produced ID/AST results in approximately 8.88hr (IQR = 8.10-9.67), over 40hr faster
than conventional ID/AST (P < .001).34 AxDx cut AST time alone by approximately
27hr. The study focused on gram-negative agreement with conventional cultures and

20

found that AxDx correctly identified 102 of 105 monomicrobial samples (97.1%) and 10
of 10 polymicrobial samples (100%). Of the 13 incorrectly identified samples, 8
contained species not covered by the panel. AST agreement between AxDx and
conventional cultures was 96.4%. They found 1.4% minor discrepancies 2.3%, major
discrepancies 2.3%, and 1.0% very major discrepancies between methods. Of note,
seven ESBL-producing E. coli and three MDR P. aeruginosa isolates were included in
the evaluation, and AxDx correctly identified resistance and did not report false
susceptibility.
In a comprehensive study by Pancholi et al (2017) for all pathogens covered by
AxDx, a total of 1,940 samples were tested for ID/AST against standard lab methods.35
AxDx provided an overall sensitivity of 97.5% (95% CI, 96.7-98.1) and specificity of
99.5% (95% CI, 99.4-99.5). A unique feature of AxDx is the ability to make a
“monomicrobial call,” wherein it can accurately determine if a sample contains only one
species. When tested, the positive predictive value for monomicrobial samples was
97.3% (95% CI, 95.9- 98.2), and when missed samples were corrected using the
accompanying Gram stain, the PPV rose to 99.4% (95% CI, 98.5-99.7).35 This
information could reassure providers that no further workup is necessary and result in a
more rapid de-escalation of therapy.
A feature worth mentioning is AxDx’s capacity to indicate if a detected species is
not part of the regular panel, prompting further investigation in the lab. Another potential
benefit of this system is the limited hands-on time required for operation. In a study by
Charnot-Katsikas et al (2018), hands-on time was reduced by 25min on average
compared to standard methods.36
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These and other studies demonstrating the speed and accuracy of AxDx indicate
the potential of this system to positively impact patient care.36,37 With the possibility of
reducing lab wait times by days and starting patients on appropriate therapy within hours,
we could see significant improvements in BSI sepsis outcomes. Upon review of past
studies investigating mRDTs and the limitations noted therein, a randomized, controlled
clinical trial comparing AxDx to conventional methods as it pertains to patient outcomes
is a logical and much needed next step.
2.5 Review of Antimicrobial Stewardship Programs
Along with the importance of identifying pathogens and their resistance to
medications, an ASP’s role in streamlining treatment for infectious disease is crucial.16
By reducing the use of unnecessary antibiotics, an ASP can improve patient outcomes,
ensure cost-effective therapy, and reduce adverse effects of broad-spectrum antibiotic
use, most importantly antibiotic resistance.16 Huang et al (2013) compared use of
MALDI-TOF identification with antimicrobial susceptibility testing AST results before
ASP implementation (control) and after ASP implementation (intervention) in a quasiexperimental study (N = 501).38 Comparison of intervention to control showed a
significant difference in ICU LOS (8.3 [SD = 24.2] vs 14.9 [SD = 9.0] days; P = .014),
30-day all-cause mortality (12.7% vs 20.3%; P = .021), faster time to effective therapy
(20.4 vs 30.1 hours; P = .021), and faster time to optimal therapy (47.3 vs 90.3 hours; P
< .001). It is important to note that there was no significant difference found in overall
LOS and that possible confounding factors such as changes in standard of care, seasonal
variations, or maturation bias of hospital staff could not be controlled.
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Banerjee et al (2015) published a non-blinded, randomized, controlled trial
comparing PCR mRDT with ASP (n = 212), without ASP (n = 198), and standard
culturing (n = 207).39 The study was not adequately powered to show differences in LOS,
mortality, or hospital costs, but they found a significant difference in TAAT between
mRDT with ASP and the other two arms. De-escalation to appropriate antibiotics in
mRDT with ASP was 21hr, mRDT alone was 38hr, and control was 34hr (P < 0.001).
Escalation to appropriate antibiotics in mRDT with ASP was 5hr, mRDT alone was 6hr,
and control was 24hr (P = .04).
Upon review, it is clear that the information garnered from mRDT is more
effectively understood and utilized when results are communicated through an ASP. Our
findings support the Infectious Diseases Society of America’s recommendation that ASP
be used in conjunction with mRDT for BSI.16 For our study, we feel it is imperative that
the ASP works in close concert with both lab and clinician to interpret test findings and
relay recommendations in a timely manner in order to maximize the benefits of using
AxDx.
2.6 Summary of the Proposed Study
As of this writing there have been no RCTs comparing AxDx to conventional
methods in regard to patient outcomes, although one such study is currently recruiting.
Moreover, upon reviewing the current studies investigating mRDTs, the need for a
randomized, controlled trial examining patient outcomes is clear. Many of the
aforementioned studies, some more conclusively than others, showed improvement in
patient outcomes with the use of mRDTs. They most commonly found reductions in ICU
LOS, HLOS, TAAT, and, to a lesser degree, mortality. As our population of interest
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includes only ICU patients, we are confident that choosing ICU LOS as our primary
outcome will show the greatest measurable effect. Early and accurate diagnosis of sepsis
is a key factor, and the use of SOFA in the ICU will help us identify patients most at risk
for critical illness due to BSI. The participation of an ASP to guide treatment and track
local resistance patterns has been proven to be a crucial part in the care and management
of sepsis patients. Finally, with the use of AxDx, which has demonstrated high
sensitivity, specificity, and considerably faster results than conventional methods, we
hope to show significant differences in patient outcomes.
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Chapter 3: Methods
3.1 Study Design
A prospective, randomized-controlled trial will be conducted at Yale New Haven
Hospital for 24 consecutive months. Outcomes will be assessed for two groups receiving
treatment based on diagnostic results from the Accelerate Pheno™ System versus
standard culturing methods.
3.2 Study Population and Sampling
Eligible patients are adults (≥18 years) with SOFA scores greater than or equal to
2, who have positive blood culture results, and who are currently admitted to the
following ICUs: medical (MICU), cardiac (CCU), cardiothoracic (CTICU), surgical
(SICU) and neurocritical (NICU). Written informed consent will be procured from all
patients or their power of attorney. If consent cannot be given during emergency
situations, the FDA’s guidelines on exceptions from informed consent will be followed.1
Patients excluded meet the following criteria: (1) those with sepsis admitted to other
units; (2) those with positive blood cultures in the preceding week; (3) those who decline
participation; (4) those previously enrolled in the study; (5) those who die or are
transferred off the unit within 24 hours of enrollment; or (6) those with positive cultures
suspected to be contaminated by skin flora.
3.3 Subject Protection and Confidentiality
We will gain approval from Yale’s Institutional Review Board (IRB) by
satisfying all application requirements, providing a detailed study protocol, and eliciting
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informed consent from subjects or power of attorney. The consent form (Appendix A)
will outline the study in easily understood language, including risks and benefits of
participation, as well as the exchange of personal health information (PHI) with the
investigation team. We will follow all requirements for human subject research set forth
by the Yale Human Research Protection Program.
All members of the investigation team will complete the human research
requirements set forth by Yale, which include an initial web-based training program,
Health Insurance Portability and Accountability Act (HIPPA) Training, and Good
Clinical Practice Training prior to the start of the study. All information obtained during
the study will be stored in an encrypted database. Select members of the research team
will be allowed access to the data and only then by way of individual user IDs and
passwords. University resources for data encryption (Bitlocker, FileVault), storage and
document management (Secure Box, Storage@Yale), and a virtual private network
(VPN) will be utilized in accordance with Yale Information Technology Services
guidelines.
In order to protect patients and ensure ethical treatment, samples from the
intervention group will also be processed using standard culturing and sensitivity
methods. If additional blood samples are needed to accommodate this safeguard, they
will be collected from all participants. Should a discrepancy between results arise,
clinicians will make ultimate decisions regarding management and treatment.
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3.4 Recruitment and Enrollment
During the 22-month rolling recruitment period, the research team will screen
patients at YNHH for inclusion criteria. Once informed consent is given, participants
will be enrolled in the study and randomized to either an intervention or a control group.
3.5 Study Variables and Outcome Measures
Assignment of intervention
Stratified randomization will be based on age (<65 or ≥65 years). Enrolled
patients will be randomized 1:1 to either standard blood culture processing or Accelerate
Pheno™ (AxDx). Patients will be blindly randomized and given a unique numeric
identification code using most the current version of random allocation software.
Intervention and Control Variables
The independent variable will be the use of AxDx on positive blood culture
samples. Specimens will be processed according to the manufacturer’s specifications.
Once the identity of microbial species and antimicrobial susceptibility are resulted, the
ASP will be notified. ASP will interpret results and discuss appropriate treatment options
with the patient’s medical providers.
The active control group will be those whose samples are processed using
standard YNHH culturing and sensitivity methods. Conveyance of results to ASP, as
well as review and recommendations to providers, will follow the same protocol as in the
intervention group. In both groups, providers will oversee the ordering and
administration of treatment for their patients.
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Dependent Variables
The primary outcome measured in this study will be ICU LOS, which will be
measured quantitatively as a mean. A secondary outcome will be HLOS also measured as
a mean. Other outcomes of interest to our investigators include 30-day mortality—
measured as an incidence proportion of participants who die within 30 days of
enrollment—and time to appropriate antimicrobial therapy (TAAT) measured
quantitatively using means.
Blinding
Due to different laboratory methods between intervention and control, it will not
be possible for lab personnel to be blinded to group assignments. Providers will not know
group assignments at time of randomization so initial antibiotic therapy will be
unaffected, but due to time-to-result differences between intervention and control,
blinding of providers is not possible beyond enrollment. The research personnel
reviewing electronic medical records (EMR) for outcomes of interest cannot be blinded
to group assignments. Patients and investigators assessing outcome measures, however,
will be blinded.
3.6 Data Collection
Baseline and Follow-up Data
Baseline demographic and clinical data of participants will be obtained at time of
enrollment. Primary and secondary outcome measures will be assessed 30 days after
enrollment. All information regarding hospital course will be retrieved from each
participant’s EMR. Research assistants will collect and compile data in the secured study
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database and assign a computer-generated study identification number to each
participant.
Confounding Data
Potential confounding variables that we plan to control for in this study include
demographic information such as age, sex, and ICU location at enrollment. Clinical
confounding factors include comorbidities, source of infection (if clinically evident), and
severity of illness.
3.7 Sample Size Calculation
We used the statistics application PS: Power and Sample Size Calculation
(version 3.1.2, Dale Plummer 2014) to compare two means for a two-sided hypothesis
with a confidence level of 5% and power of 80%. We assumed an expected difference of
effect measured as mean ICU LOS of 2 days with a standard deviation of 8.8. This
resulted in a total sample size of 610 or 305 per arm. Factoring in a 1% attrition rate to
each arm (lost to follow up prior to 30 days) results in a final sample size of 616 or 308
participants per arm. Details on sample size calculation can be found in Appendix B.
3.8 Data Analysis
Data collected during this study will be analyzed using statistical analysis
software. Baseline characteristics of both groups collected at enrollment will be analyzed
using standard parametric methods. To avoid confounding, continuous variables will be
analyzed using Chi-square, while Student t-tests will be used to analyze categorical
variables. The primary outcome of mean ICU LOS will be compared between
intervention and control groups using Student t-test. Other outcomes such as mean
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HLOS and mean TAAT will also be compared using Student t-tests. Incidence of 30-day
mortality will be given as a percentage and proportion using Chi-square test. Simple
logistic regression and multiple linear regression analyses will be used to control for
significant differences in covariates between the groups at baseline.
3.9 Timeline and Resources
Our study will be carried out over 24 consecutive months at YNHH York Street
Campus. Recruitment will be on a rolling basis throughout the first 22 months.
Enrollment will end on the first day of month 22, allowing for the final participants to be
followed for 30 days and for data collection and analysis to be performed over the final
month.
Accelerate Diagnostic, Inc. will provide all funding necessary for this study,
including appropriate number of Accelerate Pheno™ kits to accommodate specimen
processing in the YNHH lab. Accelerate will also provide any necessary training to
laboratory staff.
Study personnel will be include primary investigator and thesis advisor, Matthew
Grant, MD, and student primary investigator, Julie Gedalecia, PA-SII. Research
assistants will be required to relay questions and concerns from ICU and lab staff to the
investigation team. They will perform data collection from EMR throughout the study
and compile information into the database. A secured, dedicated office and computer
will be necessary for data collection and analysis. A biostatistician will assist in
developing randomization procedure for enrollment, as well as performing all statistical
analyses. Cooperation from ICU sites will be necessary to coordinate recruitment and
enrollment.
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Chapter 4: Conclusion
4.1 Advantages and Disadvantages
Very few RCTs measuring patient outcomes in relation to mRDTs have been
published. Ours would be the first RCT evaluating AxDx’s clinical impact on patients in
a head-to-head comparison with standard culture techniques. An advantage of our study
design over previous research will be 1:1 randomization of participants, which will allow
us to control for confounding factors. To reduce the chance of bias, our study participants
will be blinded to assignments whenever possible, as explained in the methods section.
This study will be conducted at a large, urban academic hospital and may not be
generalizable to smaller facilities in different geographical areas. Such smaller facilities
might not have a round-the-clock ASP for consultations or laboratory space to implement
new equipment. Regional rates of resistance can also vary greatly, and while Yale-New
Haven Hospital has a relatively low incidence of carbapenem-resistant
Enterobacteriaceae, hospitals in Boston, New York City, and Philadelphia see much
higher rates (M. Grant, MD, oral communication, Aug 2018). BSIs and sepsis are not
exclusive to the ICU, and studies will need to be conducted testing outcomes in
populations on the floors and in the emergency department. Finally, our choice to
exclude pediatric patients is based on their omission from the Sepsis-3 study.1 The task
force pointed out the need for updated criteria taking into account this population’s “agedependent variation in normal physiologic ranges and in pathophysiologic responses.”
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4.2 Clinical and Public Health Significance
The potential of AxDx to reduce TAAT by hours, if not days, could have a
substantial, positive effect on patient outcomes. In a retrospective study of septic ICU
patients with BSI conducted by Zhang et al (2017), TAAT was an independent
determinant of attributable ICU LOS.2 For every hour of appropriate treatment delay,
there was a 0.095-day increase in ICU LOS from time of blood culture collection (95%
CI, 0.057-0.132; P < .001). Likewise, every hour of delayed effective treatment saw a
0.134-day increase in attributable HLOS (95% CI, 0.074-0.194; P < .001). Initiation of
appropriate treatment could result in patients suffering from fewer toxic events due to
shorter periods of broad-spectrum antimicrobial treatment.3 Studies have also shown that
patients with long exposure to antimicrobials have an increased risk of acquiring
secondary infections such as C. difficile.4 From a stewardship standpoint, an expeditious
switch from broad-spectrum antimicrobials to more tailored therapies can help reduce the
spread of antimicrobial resistance.5
Although not addressed explicitly in our review, the fiscal implications of
reducing morbidity and mortality from sepsis should not be overlooked. According to a
comprehensive study by Paoli et al (2018), sepsis ranks highest of all disease states in
management costs.6 In the US in 2013, the $24 billion spent on sepsis care made up
approximately 13% of all hospital costs. At roughly $18,000 per hospitalization, sepsis
ranks a comfortable first place, before osteoarthritis at ~$16,000 per stay and childbirth at
~$3500 per stay. In another analysis of critical care in the US by Halpern and Pastores
(2010), the daily cost of an ICU bed averaged $3500.7 Despite our understanding of the
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financial burden sepsis places on patients and the healthcare system, the practical
question is whether or not the benefits of these new technologies outweigh the costs.
According to a representative from Accelerate, the list price of a system, which
includes a computer used for analysis and two test modules that can process one sample
each, is roughly $200,000. Each additional module is $80,000 with a maximum of four
modules per computer system. The AxDx single-use, single-sample test cartridges cost
roughly $200-250 each (phone communication, C. Peburn, Aug 2018). Theoretically,
with an initial investment of $360,000 (one system with four modules), a hospital would
recover these costs if ICU LOS decreased by one day for approximately 110 patients.
According to national estimates of ICU admissions for sepsis (~14.6%)8 and mean ICU
LOS (6.4 days)9, total cost from a system-wide perspective could be swiftly recuperated.
While AxDx promises to deliver a wealth of valuable information to providers
and clinically beneficial outcomes to patients, these claims need to be evaluated in realworld settings. The results of our literature review and study will hopefully inspire
further RCTs in this area. With the variety of mRDTs available and in development,
sound research is needed in order to move us toward the next generation of diagnostic
tests, as complications from serious blood-stream infections continue to exact an
enormous toll on human health.
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Appendix A: Adult Consent Form

COMPOUND AUTHORIZATION AND CONSENT FOR PARTICIPATION IN A
RESEARCH PROJECT
200 FR. 1 (2016-2)
YALE UNIVERSITY SCHOOL OF MEDICINE
YALE NEW HAVEN HOSPITAL

Study Title: Does Use of a Molecular Rapid Pathogen Kit Improve Outcomes in the
Bacteremic and Critically Ill?
Study arms: Accelerate Pheno System ID/AST versus conventional culture and
sensitivity
Principal Investigators: Julie Gedalecia, PA-SII, Matthew Grant, MD
Invitation to Participate and Description of Project
You are invited to participate in a research study designed to look at the comparison
of a rapid diagnostic blood test versus standard blood test in the diagnosis and treatment of
blood stream infection. You have been asked to participate because you are an ICU patient
who has been diagnosed with sepsis by meeting two or more criteria (SOFA score) and
having a blood culture that is positive for bacteria. This is a study is being carried out at
Yale New Haven Hospital York Street Campus.
In order to decide whether or not you wish to be a part of this research study you
should know enough about its risks and benefits to make an informed decision. This
consent form gives you detailed information about the research study, which a member of
the research team will discuss with you. This discussion should go over all aspects of this
research: its purpose, the procedures that will be performed, and any risks of the procedures,
possible benefits, and possible alternative treatments. Once you understand the study, you
will be asked if you wish to participate; if so, you will be asked to sign this form.

Description of Procedures
If you agree to participate in this study, information from your medical records will be
made available to the research team including age, sex, past medical history, past surgical
history, medications, and allergies. Information specific to the study will be reported to the
research team by lab personnel and your primary clinicians. This is done to compare the
two groups to one another. All information is outlined in the following chart and will be
reported at time of enrollment.

Medical information includes:
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▪
▪
▪

Age, sex
A measurement of your current level of disease known as the Sequential Organ
Failure Assessment (SOFA)
The reason you were admitted to the ICU

If you are an appropriate candidate for this study, you will be placed into either the
intervention group or a control group; the intervention group has blood tested with the
Accelerate system and the control group has blood tested with standard techniques. To date,
there is no information supporting one test as superior to the other in terms of length of
stay and survival. Random assignment occurs through a computer based system in which
you have an equal chance of being placed in either the intervention or control group. Both
you and your providers will be blinded to which test you receive, and all patients will be
treated the same in terms of initial treatment for suspected blood infection. Once assigned
to the group, you will be given an individualized study code to help maintain further
privacy of your medical records.
We will be measuring the primary outcome of length of stay in the ICU along with three
secondary outcomes. These outcomes will be reported at 30 days. 30 days from when you
are entered into the study will mark the conclusion of the trial. You will continue your
treatment and/or hospital stay if necessary but there will be no more information collected
past this point. After the two-year study timeframe and data analysis, all identifying
information will be deleted to maintain your privacy. Both test methods require the same
amount of blood, approximately 140mL of blood, which is a little less than 5oz. All patients
with suspected blood infection, not just those in this study, get this amount of blood drawn
in our institution. Other outcomes are determined in respect to guidelines and clinical
assessment, as listed below.
Other Measurements: 90-day survival, length of hospital stay, time to appropriate treatment
If you agree to participate in this study, you will be asked to:
▪ Consent to randomly being assigned to the Accelerate or standard group
▪ Consent to be blinded to test used
▪ Consent to allow access of the primary research team to your medical records, to
obtain the information outlined above at the time of enrollment in the trial and up
to 30 days after.
▪ Repeat blood draws may be necessary if results from either test are inconclusive
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as
required by U.S. Law. This Web site will not include information that can identify you.
At most, the Web site will include a summary of the results. You can search this Web site
at any time.
You will be told of any significant new findings that are developed during the course of
your participation in this study that may affect your willingness to continue to participate.

Risks and Inconveniences
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Currently there is evidence that Accelerate is superior to standard technique in terms of
patient outcomes. Accelerate has been measured against standard technique and has a
significant level of agreement. This study potentially changes speed at which treatment is
delivered, so there is some risk of being treated slower than the standard of care.
However, since standard of care technique will be performed on all participants, should
there be a failure of Accelerate to deliver a result, we will use the standard technique
results to formulate a treatment plan. Since you are a patient in a critical care unit,c there
are common risks associated with being in the ICU such as:
▪
▪
▪
▪
▪

Death
Worsening of illness with possibility of the need for life support through
mechanical ventilation or blood pressure supporting drugs
Renal failure requiring renal replacement therapy such as dialysis
Other organ failure
Secondary infection

Additionally, blood tests have some minor risks associated with them such as swelling
bruising, and bleeding, feeling lightheaded or nauseous, and rarely infection at the site from
where blood was drawn. Our clinical team will take all necessary steps to maintain a
sanitary environment and use proper technique to prevent infection and limit pain.
As we are collecting medical information, there is risk of loss of confidentiality. We are
complying with all guidelines taking every step to ensure that your private information is
secure. Identifying information will only be stored on a single online document at the
primary research center, to be deleted following conclusion of the study.

Benefits
Participation in this study allows you to randomly be assigned to either Accelerate
or standard technique as your blood test method. There may be the benefit that
being assigned to the experimental intervention, Accelerate, yields a shorter length
of stay or higher incidence of survival as compared to the standard technique.
Furthermore, this study may help direct the way in which we test patients who have
serious blood infections, its results having the potential to help many patients in
future.
Economic Considerations
Regardless of randomization, both tests will be provided to you are at no cost.
Adverse effects as a result of the blood tests will be treated at no cost as well. You
will be responsible for any co-pays required by your insurance company for
treatment of your illness.
Treatment Alternatives
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If you decide not to participate in this study, you will be tested using standard
technique.
Confidentiality
Any identifiable information that is obtained in connection with this study will
remain confidential and will be disclosed only with your permission or as required
by U.S. or State law. Examples of information that we are legally required to
disclose include abuse of a child or elderly person, or certain reportable diseases.
Compliance information and compliance requirements mandated by Health
Insurance Portability and Accountability Act (HIPAA) will be reviewed and
employed in our study design. This specifically encompasses both cyber and
physical security. Additionally, all subjects will be assigned individualized
numbers to remove identifying factors; Patient identification numbers and
information will be stored in a singular master list, remaining on a secure server
that will be deleted following study completion after a 2-year study period and data
analysis. When the results of the research are published or discussed in conferences,
no information will be included that would reveal your identity unless your specific
consent for this activity is obtained.
Representatives from the Yale Human Research Protection Program, the Yale
Human Investigation Committee (the committee that reviews, approves, and
monitors research on human subjects) may inspect study records during internal
auditing procedures. However, these individuals are required to keep all
information confidential.
Information about your study participation will be entered into your Electronic
Medical Record (EMR). Once placed in your EMR, these results are accessible to
all of your providers who participate in the EMR system. Information within your
EMR may also be shared with others who are appropriate to have access to your
EMR (e.g. health insurance company, disability provider.)
In case of Injury
If you are injured while on study, seek treatment and contact the study doctor as
soon as you are able.
Yale School of Medicine and Yale-New Haven Hospital do not provide funds for
the treatment of research-related injury. If you are injured as a result of your
participation in this study, treatment will be provided. You or your insurance
carrier will be expected to pay the costs of this treatment. No additional financial
compensation for injury or lost wages is available.
You do not give up any of your legal rights by signing this form.

Voluntary Participation and Withdrawal
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Participating in this study is voluntary. You are free to choose not to take part in this
study. Refusing to participate will involve no penalty or loss of benefits to which you are
otherwise entitled (such as your health care outside the study, the payment for your health
care, and your health care benefits). However, you will not be able to enroll in this
research study and will not receive study procedures as a study participant if you do not
allow use of your information as part of this study.
If you do decide to take part in this study, you are free to stop and withdraw from this
study at any time during its course. Patients maintain the right to refuse the blood test.
Once withdrawn from the trial, your illness treatment will be managed at the discretion of
the primary clinical team.
To withdraw from the study, you can call a member of the research team at any time and
tell them that you no longer want to take part. The researchers may withdraw you from
participating in the research if necessary. This may occur under the conditions that you
are found to be participating in another clinical trial.
Withdrawing from the study will involve no penalty or loss of benefits to which you are
otherwise entitled. It will not harm your relationship with your own doctors or with the
hospital.
When you withdraw from the study, no new health information identifying you will be
gathered after that date. Information that has already been gathered may still be used and
given to others until the end of the research study, as necessary to insure the integrity of
the study and/or study oversight.
Questions
We have used some technical terms in this form. Please feel free to ask about anything
you don't understand and to consider this research and the consent form carefully—as long
as you feel is necessary—before you make a decision.
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Authorization

I have read (or someone has read to me) this form and have decided to participate in the
project described above. Its general purposes, the particulars of my involvement and
possible hazards and inconveniences have been explained to my satisfaction. My signature
also indicates that I have received a copy of this consent form.
Name of Subject:_____________________________

Signature:___________________________________
Date:______________________________________
In the event the participant has impaired decision-making capacity, I have decided to
allow participation in the project described above. Its general purposes, the particulars of
involvement and possible hazards and inconveniences have been explained to my
satisfaction. My signature also indicates that I have received a copy of this consent form.
Durable Power of Attorney for Health Care Name:
Signature:
Date:______________________________________

___________________________________________
Signature of Principal Investigator

___________________
Date

-or___________________________________________
Signature of Person Obtaining Consent

___________________
Date

If you have further questions about this project or have a research-related problem, you
may contact Principal Investigators, Julie Gedalecia, PA-SII or Dr. Matthew Grant, MD.
If, after you have signed this form you have any questions about your privacy rights,
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with
someone other than the researchers to discuss problems, concerns, and questions you may
have concerning this research, or to discuss your rights as a research subject, you may
contact the Yale Human Investigation Committee at (203) 785-4688.
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Appendix B: Sample Size Calculation

In a previous study by Rhee et al. (2017)1 reviewing nearly 3 million adult EHRs, the
mean ICU LOS for patients with sepsis was 6.4 days (SD = 8.8). Our aim is to detect a
mean change difference of 2 (SD = 8.8) between the groups in our study.
Sample size was calculated with PS: Power and Sample Size Calculations (version 3.1.2,
Dale Plummer 2014) in August 2018.
Power (1-β)
Type 1 error (α)
Number of tails
Mean change
Standard Deviation

0.80
0.05
2
2.0
8.8

305 subjects per arm or 610 subjects total is the raw sample size.
Estimating for a 1% loss to follow-up, the final sample size is 308 subjects per arm or
616 total subjects.
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